N/A
Completed N=14
Meibomian Gland Dysfunction Treatment
Source: ClinicalTrials.gov NCT04229888 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcomePrimary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02
Summary
The purpose of this study is to evaluate the effectiveness of treatments for Meibomian Gland Dysfunction.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dry Eye Questionnaire 5 (DEQ-5) Score |
11.8; 11.8 | 0.02 sig |
| SECONDARY Meibomian Gland Score |
53.2; 52.6 | 0.07 |
| SECONDARY Tear Break-Up Time (TBUT) |
7.11; 5.62 | 0.66 |
Eligibility Criteria
Inclusion Criteria
- evidence of meibomian gland obstruction in both eyes
- dry eye symptoms per DEQ-5
Exclusion Criteria
- active ocular infection
- previous LipiFlow treatment
- beginning new oral or other systemic medications within prior 3 months
- beginning new or changing dosages of ocular medications within prior 3 months
- previous ocular surgery, trauma, herpes, recurrent inflammation, punctal plugs in prior 3 months
- habitual contact lens wear in prior 3 months
- women who are pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT04229888). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.